Posted on by Indian Scientist

Dr. Bijesh Biswal | Cell Biology | Excellence in Research Award

National Institute of Technology Rourkela | India

Dr. Bijesh Kumar Biswal is an Associate Professor at the Cancer Drug Resistance Laboratory, Department of Life Science, National Institute of Technology Rourkela, India. He holds a Ph.D. in Cancer Biology from IIT Madras and has completed postdoctoral research at Rutgers University and Dartmouth College, USA. His research focuses on cancer biology, particularly transcriptional regulation, drug resistance mechanisms, and exosome-mediated drug delivery. Dr. Biswal has authored over 60 publications and has been cited more than 1,100 times, reflecting his significant contribution to the field. He has mentored 3 Ph.D. students and 15 Master’s students, with several ongoing research projects. His work has been recognized with awards such as the Best Faculty Advisor Award from NIT Rourkela and the Early Career Research Award from SERB, DST, New Delhi. Dr. Biswal is a life member of the Indian Association of Cancer Research and the Society of Biochemists India. His research continues to influence cancer therapeutics and drug resistance studies.

Profiles: Google Scholar | Orcid

Featured Publication

Tripathi, S. K., Panda, M., & Biswal, B. K. (2019). Emerging role of plumbagin: Cytotoxic potential and pharmaceutical relevance towards cancer therapy. Food and Chemical Toxicology, 125, 566–582.

Tripathi, S. K., & Biswal, B. K. (2020). Piperlongumine, a potent anticancer phytotherapeutic: Perspectives on contemporary status and future possibilities as an anticancer agent. Pharmacological Research, 156, 104772.

Panda, M., Tripathi, S. K., & Biswal, B. K. (2021). SOX9: An emerging driving factor from cancer progression to drug resistance. Biochimica et Biophysica Acta (BBA) – Reviews on Cancer, 1875(2), 188517.

Panda, M., & Biswal, B. K. (2019). Cell signaling and cancer: A mechanistic insight into drug resistance. Molecular Biology Reports, 46(5), 5645–5659.

Mao, P., Hever-Jardine, M. P., Rahme, G. J., Yang, E., Tam, J., Kodali, A., Biswal, B., … (2013). Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma. PLoS One, 8(11), e81803.

Bijesh Biswal | Cell Biology | Excellence in Research Award

You May Also Like